NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Forecast, Price & News $17.57 +0.08 (+0.46%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$17.24▼$17.7850-Day Range$16.98▼$20.3752-Week Range$7.24▼$30.10Volume406,299 shsAverage Volume648,547 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$37.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Protagonist Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside110.6% Upside$37.00 Price TargetShort InterestHealthy4.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.35) to ($2.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector631st out of 976 stocksPharmaceutical Preparations Industry301st out of 455 stocks 3.5 Analyst's Opinion Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.00, Protagonist Therapeutics has a forecasted upside of 110.6% from its current price of $17.57.Amount of Analyst CoverageProtagonist Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.87% of the outstanding shares of Protagonist Therapeutics have been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 1.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTGX. Previous Next 1.7 News and Social Media Coverage News SentimentProtagonist Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Protagonist Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Protagonist Therapeutics are expected to grow in the coming year, from ($2.35) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -6.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Protagonist Therapeutics (NASDAQ:PTGX) StockProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Read More PTGX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTGX Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Cut to $34.00 by Analysts at JPMorgan Chase & Co.September 26, 2023 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 3.9% on Analyst DowngradeSeptember 28, 2023 | MarketBeat Internal (Ad)30 Days of MarketBeat All Access FreeAccess our premier stock research platform that includes research tools, stock screeners, instant alerts, real-time news and much more. September 26, 2023 | msn.comJP Morgan Maintains Protagonist Therapeutics (PTGX) Overweight RecommendationSeptember 24, 2023 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at StockNews.comSeptember 5, 2023 | finance.yahoo.comProtagonist Therapeutics to Present at Upcoming Investor ConferencesAugust 9, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Receives $34 Million from Warrant ExercisesAugust 9, 2023 | finance.yahoo.comProtagonist Receives $34 Million from Warrant ExercisesSeptember 28, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 4, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), Dynavax (DVAX)August 3, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | finance.yahoo.comProtagonist Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 22, 2023 | finance.yahoo.comPTGX - Protagonist Therapeutics, Inc.July 18, 2023 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Reports Granting of Inducement AwardJuly 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and KalVista Pharmaceuticals (KALV)July 6, 2023 | msn.comJMP Securities Maintains Protagonist Therapeutics (PTGX) Market Outperform RecommendationJuly 6, 2023 | msn.comExpert Ratings for Protagonist TherapeuticsJuly 6, 2023 | markets.businessinsider.comAnalyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data ImpressiveJuly 5, 2023 | markets.businessinsider.comJMP Securities Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)July 5, 2023 | finance.yahoo.comProtagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival TreatmentJuly 4, 2023 | msn.comPiper Sandler Reiterates Protagonist Therapeutics (PTGX) Overweight RecommendationJuly 4, 2023 | msn.comBTIG Reiterates Protagonist Therapeutics (PTGX) Buy RecommendationJuly 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Protagonist Therapeutics (PTGX) and Arcus Biosciences (RCUS)July 4, 2023 | finance.yahoo.comProtagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque PsoriasisJuly 3, 2023 | fool.comProtagonist Therapeutics (NASDAQ: PTGX)July 3, 2023 | benzinga.comAstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On MondayJune 30, 2023 | finance.yahoo.comProtagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's WhySee More Headlines Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Company Calendar Last Earnings8/03/2023Today9/28/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTGX CUSIPN/A CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.00 High Stock Price Forecast$41.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+110.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-127,390,000.00 Net MarginsN/A Pretax Margin-16,319.91% Return on Equity-56.78% Return on Assets-50.48% Debt Debt-to-Equity RatioN/A Current Ratio12.01 Quick Ratio12.01 Sales & Book Value Annual Sales$26.58 million Price / Sales38.03 Cash FlowN/A Price / Cash FlowN/A Book Value$4.38 per share Price / Book4.01Miscellaneous Outstanding Shares57,530,000Free Float54,654,000Market Cap$1.01 billion OptionableNot Optionable Beta1.86 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 66)CEO, Pres, Sec. & Director Comp: $883.46kDr. Suneel K. Gupta Ph.D. (Age 65)Chief Devel. Officer Comp: $640.89kDr. Mark Smythe Ph.D. (Age 58)Founder & VP Technology Mr. Asif Ali (Age 49)Exec. VP & Chief Financial Officer Mr. Mohammad Masjedizadeh Ph.D.Exec. VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 52)Exec. VP & Gen. Counsel Ms. Carena SpiveySr. VP of HRDr. Ashok Bhandari Ph.D. (Age 59)Exec. VP & Chief Drug Discovery and Preclinical Devel. Officer Dr. Scott Eric Plevy M.D.Exec. VP & Therapeutic Head of GastroenterologyMr. Carter J. King (Age 52)Sr. VP of Bus. Devel. More ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXOmniAbNASDAQ:OABIZymeworksNYSE:ZYMECibusNASDAQ:CBUSAura BiosciencesNASDAQ:AURAView All CompetitorsInstitutional OwnershipPerceptive Advisors LLCBought 504,609 shares on 8/24/2023Ownership: 2.555%California State Teachers Retirement SystemBought 7,934 shares on 8/21/2023Ownership: 0.100%Nuveen Asset Management LLCBought 107,490 shares on 8/16/2023Ownership: 1.627%Zacks Investment ManagementSold 909 shares on 8/15/2023Ownership: 0.019%Walleye Trading LLCSold 900 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions PTGX Stock - Frequently Asked Questions Should I buy or sell Protagonist Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTGX shares. View PTGX analyst ratings or view top-rated stocks. What is Protagonist Therapeutics' stock price forecast for 2023? 3 Wall Street research analysts have issued 1-year target prices for Protagonist Therapeutics' stock. Their PTGX share price forecasts range from $34.00 to $41.00. On average, they predict the company's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 110.6% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts. How have PTGX shares performed in 2023? Protagonist Therapeutics' stock was trading at $10.91 on January 1st, 2023. Since then, PTGX shares have increased by 61.0% and is now trading at $17.57. View the best growth stocks for 2023 here. When is Protagonist Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our PTGX earnings forecast. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.03. What ETF holds Protagonist Therapeutics' stock ? Invesco Dorsey Wright Healthcare Momentum ETF holds 129,690 shares of PTGX stock, representing 1.50% of its portfolio. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE). When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. What is Protagonist Therapeutics' stock symbol? Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX." Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.71%), State Street Corp (6.17%), Cowen AND Company LLC (2.90%), Cormorant Asset Management LP (2.61%), Perceptive Advisors LLC (2.55%) and Geode Capital Management LLC (1.87%). Insiders that own company stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Protagonist Therapeutics' stock price today? One share of PTGX stock can currently be purchased for approximately $17.57. How much money does Protagonist Therapeutics make? Protagonist Therapeutics (NASDAQ:PTGX) has a market capitalization of $1.01 billion and generates $26.58 million in revenue each year. The company earns $-127,390,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. How many employees does Protagonist Therapeutics have? The company employs 106 workers across the globe. How can I contact Protagonist Therapeutics? Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The official website for the company is www.protagonist-inc.com. The company can be reached via phone at (510) 474-0170 or via email at bkorb@soleburytrout.com. This page (NASDAQ:PTGX) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.